Indivior Pharmaceuticals Inc Revenue Growth Rates (INDV), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Indivior Pharmaceuticals Inc   (NASDAQ: INDV)
 

INDV's Revenue Growth by Quarter and Year

Indivior Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INDV Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 343.00
1st Quarter March 317.00
FY 660.00





INDV Revenue second quarter 2026 Y/Y Growth Comment
Indivior Pharmaceuticals Inc achieved in the second quarter 2026, above Company average Revenue increase of 13.58% year on year, to $ 343.00 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 120 other companies have achieved higher Revenue growth. While Indivior Pharmaceuticals Inc ' s Revenue growth of 13.58% ranks overall at the positon no. 2616 in the second quarter 2026.


INDV Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -69.7 % 8.69 % -
3rd Quarter September - 1.95 % - -
2nd Quarter June 13.58 % 1 % - -
1st Quarter March 19.62 % -6.69 % - -
FY   - -40.33 % 90.12 % -

Financial Statements
Indivior Pharmaceuticals Inc 's second quarter 2026 Revenue $ 343.00 millions INDV's Income Statement
Indivior Pharmaceuticals Inc 's second quarter 2025 Revenue $ 302.00 millions Quarterly INDV's Income Statement


INDV Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 15.02 % 286.97 % -
3rd Quarter September - 3.64 % 2.68 % -
2nd Quarter June 8.2 % 13.96 % 5.28 % -
1st Quarter March -11.94 % -77.69 % -74.02 % -
FY (Year on Year)   - -40.33 % 90.12 % -


Back to INDV Growth rate Comparisons >> Back to INDV Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #375
Overall #2616

Revenue Y/Y Growth Statistics
High Average Low
4.29 % -27.16 % -40.33 %
(Sep 30 2025)   (Dec 31 2025)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #121
Healthcare Sector #375
Overall #2616
Revenue Y/Y Growth Statistics
High Average Low
4.29 % -27.16 % -40.33 %
(Sep 30 2025)   (Dec 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Indivior Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
286.97 % 17.21 % -77.69 %
(Dec 31 2024)  


INDV's II. Quarter Q/Q Revenue Comment
Indivior Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue increase of 8.2% quarter on quarter, to $ 343.00 millions.

Within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Revenue quarter on quarter growth. While Indivior Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 927.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #140
Overall #927
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #61
Healthcare Sector #140
Overall #927
Revenue Q/Q Growth Statistics
High Average Low
286.97 % 17.21 % -77.69 %
(Dec 31 2024)  


INDV's II. Quarter Q/Q Revenue Comment
Indivior Pharmaceuticals Inc achieved in the II. Quarter 2026 below company average Revenue increase of 8.2% quarter on quarter, to $ 343.00 millions.

Within Major Pharmaceutical Preparations industry 60 other companies have achieved higher Revenue quarter on quarter growth. While Indivior Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 927.


Indivior Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 1,333.00 $ 1,292.00 $ 1,240.00 $ 2,068.00 $ 2,062.00
Y / Y Revenue Growth (TTM) -35.35 % -37.25 % -40.33 % 4.29 % -
Year on Year Revenue Growth Overall Ranking # 2157 # 2019 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 3.17 % 4.19 % -40.04 % 0.29 % 0.15 %
Seq. Revenue Growth (TTM) Overall Ranking # 2616 # 2485 # 2278 # 3145 # 0


Cumulative Revenue growth Comment
Indivior Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Indivior Pharmaceuticals Inc 's annual Revenue improvement would be -35.35% year on year to $1,333 millions.

In the Healthcare sector 320 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2019 to 2157.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 321
Overall # 2157

Revenue TTM Y/Y Growth Statistics
High Average Low
4.29 %
 -27.16 %
-40.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 375
S&P 500 # 2616
Cumulative Revenue growth Comment
Indivior Pharmaceuticals Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Indivior Pharmaceuticals Inc 's annual Revenue drop would be -35.35% year on year to $1,333 millions.

In the Healthcare sector 320 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2019 to 2157.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 321
Overall # 2157

Revenue TTM Y/Y Growth Statistics
High Average Low
4.29 %
-27.16 %
-40.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 375
S&P 500 # 2616




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INDV's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Insulet Corporation23.51%$ 23.509 millions
Veracyte Inc 23.45%$ 23.448 millions
Journey Medical Corp23.33%$ 23.326 millions
Twist Bioscience Corporation23.24%$ 23.235 millions
Axogen inc 23.06%$ 23.065 millions
Vericel Corporation22.48%$ 22.481 millions
Milestone Scientific Inc 22.28%$ 22.276 millions
Alpha Teknova Inc 22.05%$ 22.045 millions
X4 Pharmaceuticals Inc21.64%$ 21.642 millions
Exagen Inc 21.63%$ 21.629 millions
Adaptive Biotechnologies Corporation21.53%$ 21.526 millions
Privia Health Group Inc 21.39%$ 21.390 millions
Bionano Genomics Inc 21.36%$ 21.357 millions
Evolus Inc 21.30%$ 21.298 millions
Invivyd Inc 21.20%$ 21.203 millions
Transmedics Group Inc 20.70%$ 20.702 millions
Irhythm Holdings Inc 20.62%$ 20.615 millions
Delcath Systems Inc 20.60%$ 20.604 millions
Castle Biosciences Inc 20.14%$ 20.140 millions
Procept Biorobotics Corporation20.00%$ 20.004 millions
Biomarin Pharmaceutical Inc19.91%$ 19.905 millions
Cannapharmarx Inc 19.26%$ 19.261 millions
Anika Therapeutics Inc 19.18%$ 19.176 millions
Bioaffinity Technologies Inc 18.99%$ 18.992 millions
Aurinia Pharmaceuticals Inc 18.87%$ 18.872 millions
Camp4 Therapeutics Corporation18.84%$ 18.838 millions
Lensar Inc 18.37%$ 18.371 millions
Immunocore Holdings Plc18.34%$ 18.336 millions
Innovage Holding Corp 18.31%$ 18.307 millions
Koru Medical Systems Inc 18.15%$ 18.153 millions


About Indivior Pharmaceuticals Inc Revenue Growth Rates (INDV), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Indivior Pharmaceuticals Inc (CIK 1625297).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-051895
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Indivior Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.